Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab.
Evangelos J Giamarellos-BourboulisM ArgyropoulouTheodora KanniT SpyridopoulosI OttoO ZenkerR GuoN C RiedemannPublished in: The British journal of dermatology (2020)